Results 41 to 50 of about 24,414 (214)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients

JACC: Case Reports, 2020
Standard lipid-lowering therapies in solid organ transplantations pose challenges due to interactions with immunosuppressants. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a new class of lipid-lowering therapies with ...
Bruce A. Warden, PharmD, Tina Kaufman, PhD, PA-C, Jessica Minnier, PhD, P. Barton Duell, MD, Sergio Fazio, MD, PhD, Michael D. Shapiro, DO, MCR   +5 more
doaj   +1 more source

An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial.

JAMA cardiology, 2020
Importance Despite recent advances in treatment of severe aortic valve stenosis (AS), AS remains a life-threatening condition with no proven disease-modifying therapy.
B. Bergmark, M. O’Donoghue, S. Murphy, J. Kuder, M. Ezhov, R. Češka, I. Gouni-Berthold, H. Jensen, S. L. Tokgozoglu, F. Mach, K. Huber, Z. Gaciong, B. Lewis, F. Schiele, J. Jukema, T. Pedersen, R. Giugliano, M. Sabatine   +17 more
semanticscholar   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver

Neoplasia: An International Journal for Oncology Research, 2012
High circulating cholesterol is associated with hypercholesterolemia, atherosclerosis, and stroke. However, the relation between cholesterol and tumorigenesis/metastasis is controversial.
Xiaowei Sun, Rachid Essalmani, Robert Day, Abdel M. Khatib, Nabil G. Seidah, Annik Prat   +5 more
doaj   +1 more source

Plasma Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in the Acute Respiratory Distress Syndrome

Frontiers in Medicine, 2022
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that is a mediator of the immune response to sepsis. PCSK9 is also highly expressed in pneumocytes and pulmonary endothelial cells.
Thomas S. Metkus, Bo Soo Kim, Steven R. Jones, Seth S. Martin, Steven P. Schulman, Thorsten M. Leucker   +5 more
doaj   +1 more source

Perkembangan Implikasi Biologi dan Klinis Proprotein Convertase Subtilisin-Kexin 9

Majalah Kardiologi Indonesia, 2017
Pada tahun 2003 Proprotein Convertase Subtilisin-Kexin 9 (PCSK9) berhasil diidentifikasi.1 PCSK9 berfungsi meningkatkan kadar LDL Cholesterol (LDL-C) melalui degradasi LDL Receptor (LDLR).2 Penemuan PCSK9 telah merevolusi serta merupakan perkembangan ...
doaj   +1 more source

Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions

Journal of Clinical and Preventive Cardiology, 2017
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces low-density lipoprotein receptor (LDLR) recycling, leading to a decrease of LDL cholesterol
JPS Sawhney, Saurabh Bagga
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 in kidney disease

Nephrology Dialysis Transplantation, 2019
Abstract Chronic kidney disease (CKD) is associated with a substantially increased risk for the development of atherosclerotic cardiovascular (CV) disease. Accordingly, CV mortality is increased even in the earliest stages of CKD. In the general population and in CKD patients, high plasma levels of low-density lipoprotein cholesterol ...
David, Schmit, Danilo, Fliser, Thimoteus, Speer   +2 more
openaire   +2 more sources

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders

Frontiers in Neuroscience, 2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has long been studied in the liver due to its regulation of plasma low-density lipoprotein cholesterol (LDL-C) and its causal role in familial hypercholesterolemia. Although PCSK9 was first discovered
Emma M. O’Connell, F. Lohoff
semanticscholar   +1 more source

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

JACC: Case Reports, 2020
A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury.
June K. Pickett, MD, Maulin Shah, MD, Michael Gillette, PharmD, Peter Jones, MD, Salim Virani, MD, PhD, Christie Ballantyne, MD, Vijay Nambi, MD, PhD   +6 more
doaj   +1 more source

Sex difference in circulating PCSK9 and its clinical implications

Frontiers in Pharmacology, 2022
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a proprotein convertase that increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the degradation of LDL receptors (LDLRs).
Fang Jia, Si-Fan Fei, De-Bing Tong, Cong Xue, Jian-Jun Li   +4 more
doaj   +1 more source